Home > News > Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy
October 16th, 2008
Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy
Abstract:
Canaccord Adams initiates coverage on AMAG Pharmaceuticals (Nasdaq: AMAG) with a Buy rating and $57 target.
Canaccord analyst says, "Binary event but we believe data should enable first cycle approval...We acknowledge that there is controversy about whether AMAG has generated enough data for ferumoxytol approval. We believe that the Phase 3 studies demonstrated the strong efficacy and (more importantly) clean safety profile of ferumoxytol in CKD patients. We think that data also suggests that ferumoxytol may have the best safety profile, and importantly the lowest rates of anaphylaxis, of all the IV iron therapies. However, given the conservative FDA environment, we recognize that AMAG could receive a late approval or a request for more data...We believe that AMAG shares offer a compelling risk/benefit profile. AMAG shares are down almost 50% from their 52-week high in October 2007. We base our $57 price target on a pNPV analysis that assumes a 50% probability of a first-cycle approval for ferumoxytol. If ferumoxytol is approved, our pNPV analysis would yield a $95 value. If the FDA requests an additional study, our pNPV analysis would yield a $25 value."
Source:
streetinsider.com
Bookmark:
| Related News Press |
News and information
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Lab to industry: InSe wafer-scale breakthrough for future electronics August 8th, 2025
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025
ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||